Next Article in Journal
Electrophile-Induced Conformational Switch of the Human TRPA1 Ion Channel Detected by Mass Spectrometry
Next Article in Special Issue
Intensive Care Unit-Acquired Weakness: Not Just Another Muscle Atrophying Condition
Previous Article in Journal
Functional Characterization of Muscarinic Receptors in Human Schwann Cells
Previous Article in Special Issue
MBNL1-Associated Mitochondrial Dysfunction and Apoptosis in C2C12 Myotubes and Mouse Skeletal Muscle
Open AccessReview

MuRF1/TRIM63, Master Regulator of Muscle Mass

INRA, UNH, Unité de Nutrition Humaine, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(18), 6663; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21186663
Received: 18 August 2020 / Revised: 4 September 2020 / Accepted: 8 September 2020 / Published: 11 September 2020
(This article belongs to the Special Issue Muscle Atrophy: Discovery of Mechanisms and Potential Therapies)
The E3 ubiquitin ligase MuRF1/TRIM63 was identified 20 years ago and suspected to play important roles during skeletal muscle atrophy. Since then, numerous studies have been conducted to decipher the roles, molecular mechanisms and regulation of this enzyme. This revealed that MuRF1 is an important player in the skeletal muscle atrophy process occurring during catabolic states, making MuRF1 a prime candidate for pharmacological treatments against muscle wasting. Indeed, muscle wasting is an associated event of several diseases (e.g., cancer, sepsis, diabetes, renal failure, etc.) and negatively impacts the prognosis of patients, which has stimulated the search for MuRF1 inhibitory molecules. However, studies on MuRF1 cardiac functions revealed that MuRF1 is also cardioprotective, revealing a yin and yang role of MuRF1, being detrimental in skeletal muscle and beneficial in the heart. This review discusses data obtained on MuRF1, both in skeletal and cardiac muscles, over the past 20 years, regarding the structure, the regulation, the location and the different functions identified, and the first inhibitors reported, and aim to draw the picture of what is known about MuRF1. The review also discusses important MuRF1 characteristics to consider for the design of future drugs to maintain skeletal muscle mass in patients with different pathologies. View Full-Text
Keywords: MuRF1/TRIM63; TRIM E3 ligase; skeletal muscle; heart; atrophy; hypertrophy; cardiomyopathy; contractile proteins; pharmacological inhibitors; chronic diseases MuRF1/TRIM63; TRIM E3 ligase; skeletal muscle; heart; atrophy; hypertrophy; cardiomyopathy; contractile proteins; pharmacological inhibitors; chronic diseases
Show Figures

Graphical abstract

MDPI and ACS Style

Peris-Moreno, D.; Taillandier, D.; Polge, C. MuRF1/TRIM63, Master Regulator of Muscle Mass. Int. J. Mol. Sci. 2020, 21, 6663. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21186663

AMA Style

Peris-Moreno D, Taillandier D, Polge C. MuRF1/TRIM63, Master Regulator of Muscle Mass. International Journal of Molecular Sciences. 2020; 21(18):6663. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21186663

Chicago/Turabian Style

Peris-Moreno, Dulce; Taillandier, Daniel; Polge, Cécile. 2020. "MuRF1/TRIM63, Master Regulator of Muscle Mass" Int. J. Mol. Sci. 21, no. 18: 6663. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21186663

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop